Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of TAK-536 Pediatric Formulations vs Commercial Tablet
NCT02401464Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan in hypertension (HTN) (4 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose and Maximum Observed Plasma Concentration at 48 hours. Started Mar 2015; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02401464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02401464.